Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.
J Cosmet Dermatol. 2022 Dec;21(12):6568-6573. doi: 10.1111/jocd.15448. Epub 2022 Dec 12.
Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by different immunosuppressive agents.
Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology.
In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immunosuppressive therapy and its association with vaccination timing due to the decreased immunogenicity of vaccines in this setting.
Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines immunogenicity.
由于紧急情况，SARS-CoV2 疫苗在缺乏足够长期监测的情况下获得批准，因此对于接受不同免疫抑制剂治疗的患者，关于接种疫苗的时间和方案出现了一些问题。
在这里，我们介绍了皮肤科领域中此类患者的 SARS-CoV-2 疫苗接种的不同方面。
简而言之，建议所有皮肤科患者接种 SARS-CoV-2 疫苗，无论其疾病和治疗方案如何。然而，由于这种情况下疫苗的免疫原性降低，应特别考虑免疫抑制治疗及其与疫苗接种时间的关系。
新型生物免疫疗法不仅在安全性和选择性功能方面优于传统的全身治疗，而且在这方面，它们中的许多疗法不会影响疫苗的免疫原性。
